Skip to main content
    O

    Organon & Co (OGN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $13.91
    +0.01 (+0.07%)

    Market Cap: $3.65B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Organon & Co (OGN) Earnings: Report Dates and Results

    Updated Oct 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Organon (OGN) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Organon reported EPS of $0.88, below the $0.95 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    65%(15/23)
    Avg Surprise
    +5.42%

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.80
    Range$0.64 - $0.97
    9 analysts
    Revenue Consensus
    $1.56B
    Range$1.51B - $1.62B
    6 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.92
    Range$0.90 - $0.94
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.88+5.0%
    60d ago$0.88+5.0%
    30d ago$0.88+5.0%
    7d ago$0.88+5.0%
    Current$0.92
    Revenue Consensus
    $1.53B
    Range$1.53B - $1.53B
    1 analysts

    Next Report

    OGN has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 27.0% above the $0.63 reported for the quarter ended Dec 31, 2025.

    OGN Earnings Call

    The latest OGN earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, OGN beat 15 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $1.57B, down 1.9% from $1.60B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.88$0.95$0.88 - $1.05-7.37%Miss-12.9%30 up, 0 downOct 30, 2026$1.57B
    Jun 30, 2026$0.80$0.85N/A-5.88%Miss-20.0%10 up, 0 downJul 31, 2026$1.56B
    Mar 31, 2026$0.71$0.85$0.77 - $0.95-16.47%Miss-30.4%62 up, 1 downApr 30, 2026$1.46B
    Dec 31, 2025$0.63$0.73$0.62 - $0.81-13.70%Miss-30.0%70 up, 1 downFeb 12, 2026$1.51B
    Sep 30, 2025$1.01$0.93$0.89 - $0.97+8.60%Beat+16.1%51 up, 1 downNov 10, 2025$1.60B
    Jun 30, 2025$1.00$0.94$0.90 - $0.99+6.38%Beat-10.7%51 up, 0 downAug 5, 2025$1.59B
    Mar 31, 2025$1.02$0.89$0.86 - $0.94+14.61%Beat-16.4%50 up, 1 downMay 1, 2025$1.51B
    Dec 31, 2024$0.90$0.87$0.82 - $0.93+3.45%Beat+2.3%71 up, 1 downFeb 13, 2025$1.59B
    Sep 30, 2024$0.87$0.90$0.78 - $1.11-3.33%Miss0.0%70 up, 2 downOct 31, 2024$1.58B
    Jun 30, 2024$1.12$1.08$0.93 - $1.24+3.70%Beat-14.5%70 up, 2 downAug 6, 2024$1.61B
    Mar 31, 2024$1.22$0.93$0.88 - $1.22+31.18%Beat+13.0%64 up, 1 downMay 2, 2024$1.62B
    Dec 31, 2023$0.88$0.83$0.68 - $1.07+6.02%Beat+8.6%72 up, 0 downFeb 15, 2024$1.60B
    Sep 30, 2023$0.87$1.06$1.04 - $1.10-17.92%Miss-34.1%61 up, 0 downNov 2, 2023$1.52B
    Jun 30, 2023$1.31$0.99$0.94 - $1.04+32.32%Beat+4.8%60 up, 1 downAug 8, 2023$1.61B
    Mar 31, 2023$1.08$1.16$1.06 - $1.25-6.90%Miss-34.5%72 up, 0 downMay 4, 2023$1.54B
    Dec 31, 2022$0.81$0.90$0.74 - $1.03-10.00%Miss-40.9%61 up, 1 downFeb 16, 2023$1.49B
    Sep 30, 2022$1.32$1.10$0.92 - $1.39+20.00%Beat-21.0%60 up, 1 downNov 3, 2022$1.54B
    Jun 30, 2022$1.25$1.19N/A+5.04%Beat-27.3%N/A0 up, 1 downAug 4, 2022$1.58B
    Mar 31, 2022$1.65$1.30$1.14 - $1.46+26.92%Beat+4.4%61 up, 1 downMay 5, 2022$1.57B
    Dec 31, 2021$1.37$1.27$1.14 - $1.33+7.87%BeatN/A6N/AFeb 17, 2022$1.60B
    Sep 30, 2021$1.67$1.44$1.29 - $1.71+15.97%BeatN/A62 up, 0 downNov 11, 2021$1.60B
    Jun 30, 2021$1.72$1.43$1.26 - $1.57+20.28%BeatN/A3N/AAug 12, 2021$1.59B
    Mar 31, 2021$1.58$1.52N/A+3.95%BeatN/AN/AN/AJun 21, 2021$1.51B
    Last 23 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.66, down 10.9% from the year before. It was $6.34 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.66-10.9%
    Dec 31, 2024$4.11N/A
    Dec 31, 2023$4.14-17.7%
    Dec 31, 2022$5.03-20.7%
    Dec 31, 2021$6.34N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 5,300 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q4Dec 31, 20255,26912
    2025Q3Sep 30, 20256,86512
    2025Q2Jun 30, 20255,97411
    2025Q1Mar 31, 20254,48310
    2024Q4Dec 31, 20248,49312
    2024Q3Sep 30, 20245,7649
    2024Q2Jun 30, 20247,15810

    2025Q4 Earnings Call

    Opening remarks

    Jennifer Halchak Vice President, Investor Relations Thank you, operator. Good morning, everyone. With me today are Joe Morrissey, Organon's Interim Chief Executive Officer; and Matt Walsh, our Chief Financial Officer; Carrie Cox, Organon's Board Chair; and Juan Camilo Arjona Ferreira, Organon's Head of R&D, will also be joining for the Q&A portion of this call. Today, we are referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call on the Events and Presentations section of our Organon Investor Relations website. Please reference Slides 2 and 3 for a couple of brief reminders. I would like to caution listeners that certain information discussed by management during this call will include forward-looking statements. Forward-looking statements can be identified because they do not relate strictly to historical or current facts and use words such as potential, should, will, continue, expects, believe, future, estimates, believes, outlook and other words of similar meaning. Actual results could differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company's business, which are discussed in the company's filings with the Securities and Exchange Commission. This includes our most recent Form 10-K and Forms 10-Q and those amended forms. These statements are based on information as of today, February 12, 2026 and except as required by law, Organon undertakes no obligation to update or revise any of these forward-looking statements. In addition, we will discuss certain non-GAAP financial measures on this call, which should be considered a supplement to and not a substitute for financial measures prepared in accordance with GAAP. Descriptions of these measures and reconciliations to the comparable GAAP measures are included in today's earnings press release and conference call presentation, both of which are available on our Investor Relations website and have been furnished to the SEC on the current report on Form 8-K. I note that while our full year 2026 guidance measures other than revenue are provided on a non-GAAP basis, Organon does not provide GAAP financial measures on a forward-looking basis because we cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts and acquisition-related expenses. These items are uncertain, depend on various factors and could be material to our results computed in accordance with GAAP. I'd now like to turn the call over to Joe Morrissey.

    Joseph Morrissey Interim CEO Thank you, Jen. Beginning on Slide 4. In 2025, Organon delivered $6.2 billion in revenue and $1.9 billion of adjusted EBITDA. Revenue was down 3% on both a reported and ex-exchange basis.

    Frequently Asked Questions About OGN

    When is Organon's next earnings date?

    Organon's next earnings report is expected for Feb 10, 2027.

    Did OGN beat earnings estimates last quarter?

    No. Organon reported EPS of $0.88 for the quarter ended Sep 30, 2026, below the $0.95 estimate by 7.37%.

    What EPS do analysts expect from OGN next quarter?

    The consensus EPS estimate for Organon for the quarter ending Dec 31, 2026 is $0.80 from 9 analysts, with estimates from $0.64 to $0.97.

    How often does OGN beat earnings estimates?

    Organon beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -1.30%.